...
首页> 外文期刊>Minimally invasive neurosurgery: MIN >Surgical target selection in cerebral glioma surgery: linking methionine (MET) PET image fusion and neuronavigation.
【24h】

Surgical target selection in cerebral glioma surgery: linking methionine (MET) PET image fusion and neuronavigation.

机译:脑神经胶质瘤手术的手术目标选择:将蛋氨酸(MET)PET图像融合与神经导航联系起来。

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVE: The objective of this study was to investigate the histological correlate of (11)C-methionine (MET) PET uptake of brain gliomas by image fusion for navigated surgery. METHODS: Twenty-seven patients (18 male, 9 female; mean age 42 years; range 11-77 years; 8 low-grade and 11 high-grade astrocytomas or mixed gliomas, 8 oligodendrogliomas) underwent MET PET studies preoperatively. RESULTS: MET PET tumor uptake was detected in 26 of 27 patients (96.3%). The quantitative MET tumor standardized uptake value (SUV) ratio was significantly higher in malignant gliomas and oligodendrogliomas than in low-grade gliomas (2.76/2.62 vs. 1.67, p=0.03). Generally, qualitative visual grading of MET uptake revealed 2 main patterns: focal MET uptake in 12 and uniform global MET uptake in 11 patients. Focal uptake corresponded to malignant glioma histology in 66.7%, and uniform global uptake to oligodendroglial histology in 72.7%. In oligodendrogliomas, global MET uptake constituted 81.5% (range 53.8-135%) of theMRI T(1) tumor volume on average and was limited to the MRI FLAIR tumor volume in 86% (7/8) of patients. Tissue samples of focal MET uptake areas correlated with histological anaplasia in 66.6% (8/12 glioma patients), although 62.5% (5/8 patients) lacked MRI contrast enhancement. CONCLUSION: MET PET image fusion may facilitate the targeting of anaplastic foci in homogeneous MRI non-enhancing gliomas for biopsy, may identify oligodendroglial histology preoperatively as well as characterize biologically active tumor volumes within MRI T(1)/FLAIR tumor areas of candidate patients for resection.
机译:目的:本研究旨在探讨影像融合技术对脑胶质瘤的(11)C-蛋氨酸(MET)PET摄取的组织学相关性。方法:术前对27例患者进行了MET PET研究(男18例,女9例;平均年龄42岁;范围11-77岁; 8例低度星形胶质瘤或11例高级别星形胶质瘤或混合胶质瘤,8例少突胶质细胞瘤)。结果:27例患者中有26例检出MET PET肿瘤(96.3%)。恶性神经胶质瘤和少突胶质细胞瘤的定量MET肿瘤标准化摄取值(SUV)比率显着高于低度神经胶质瘤(2.76 / 2.62对1.67,p = 0.03)。一般而言,对MET摄取的定性视觉分级显示了2种主要模式:12例患者局部MET摄取和11例患者整体MET均匀摄取。局灶性摄取对应于恶性神经胶质瘤组织学的占66.7%,一致的少突神经胶质组织学的整体摄取为72.7%。在少突胶质细胞瘤中,平均MET摄取平均占MRI T(1)肿瘤体积的81.5%(范围53.8-135%),并且仅限于86%(7/8)患者的MRI FLAIR肿瘤体积。 66.6%(8/12胶质瘤患者)的局灶性MET摄取区域的组织样本与组织学增生相关,尽管62.5%(5/8患者)缺乏MRI对比增强。结论:MET PET图像融合可能有助于针对均质MRI非增强神经胶质瘤进行变性变性灶的靶向活检,可能会在术前识别少突胶质细胞学并鉴定候选患者MRI T(1)/ FLAIR肿瘤区域内的生物学活性肿瘤体积切除。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号